ArticleInvestigative radiology2019
Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping.
Article in Investigative radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- A pilot study of magnetic resonance fingerprinting and radiomics analysis in autosomal dominant polycystic kidney disease.Kidney international · 2026Article
- Multi-scanner repeatability and reproducibility of qRF-MRF breath-held and free-breathing with pilot tone in the abdomen.Magma (New York, N.Y.) · 2026Article
- Prostate Diffusion-weighted Imaging: Selecting the Optimal Repetition Time Using Synthetic Imaging Techniques.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Article
- Accelerating 2D Kidney Magnetic Resonance Fingerprinting Using Deep Learning Based Tissue Quantification.Journal of magnetic resonance imaging : JMRI · 2026Article
- Synthetic DWI: contrast improvement for diffusion-weighted imaging in prostate using T1 shine-through by synthesizing images with adjusted TR and TE.Magma (New York, N.Y.) · 2025Article
- Cross-Scanner Harmonization of AI/DL Accelerated Quantitative Bi-Parametric Prostate MRI.Sensors (Basel, Switzerland) · 2025Article
- Quantitative Prostate MRI, From theAJR. American journal of roentgenology · 2025Review
- Toward diffusion MRI in the diagnosis and treatment of pancreatic cancer.Medical oncology (Northwood, London, England) · 2025Review
- Repeatability of quantitative MR fingerprinting for TEuropean radiology · 2025Article
- Incorporating Spatial and Spectral Saturation Modules Into MR Fingerprinting.NMR in biomedicine · 2025Article
- Retrospectively Quantified T2 Improves Detection of Clinically Significant Peripheral Zone Prostate Cancer.Cancers · 2025Article
- Quantitative magnetic resonance imaging in prostate cancer: A review of current technology.World journal of radiology · 2024Review
- Feasibility of quantitative relaxometry for prostate target localization and response assessment in magnetic resonance-guided online adaptive stereotactic body radiotherapy.Physics and imaging in radiation oncology · 2024Article
- Technical note: hydrogel-based mimics of prostate cancer with matched relaxation, diffusion and kurtosis for validating multi-parametric MRI.Medical physics · 2024Article
- Emerging Trends in Magnetic Resonance Fingerprinting for Quantitative Biomedical Imaging Applications: A Review.Bioengineering (Basel, Switzerland) · 2024Review
- Quantitative Analysis of Prostate MRI: Correlation between Contrast-Enhanced Magnetic Resonance Fingerprinting and Dynamic Contrast-Enhanced MRI Parameters.Current oncology (Toronto, Ont.) · 2023Article
- Quantitative longitudinal mapping of radiation-treated prostate cancer using MR fingerprinting with radial acquisition and subspace reconstruction.Magnetic resonance imaging · 2023Article
- Novel 3D magnetic resonance fingerprinting radiomics in adult brain tumors: a feasibility study.European radiology · 2023Article
- Retrospective T2 quantification from conventional weighted MRI of the prostate based on deep learning.Frontiers in radiology · 2023Article
- Multicenter Repeatability and Reproducibility of MR Fingerprinting in Phantoms and in Prostatic Tissue.Magnetic resonance in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aims for targeted biopsy validation of magnetic resonance fingerprinting (MRF) and diffusion mapping for characterizing peripheral zone (PZ) prostate cancer and noncancers. MATERIALS AND
methodsOne hundred four PZ lesions in 85 patients who underwent magnetic resonance imaging were retrospectively analyzed with apparent diffusion coefficient (ADC) mapping, MRF, and targeted biopsy (cognitive or in-gantry). A radiologist blinded to pathology drew regions of interest on targeted lesions and visually normal peripheral zone on MRF and ADC maps. Mean T1, T2, and ADC were analyzed using linear mixed models. Generalized estimating equations logistic regression analyses were used to evaluate T1 and T2 relaxometry combined with ADC in differentiating pathologic groups.
resultsTargeted biopsy revealed 63 cancers (low-grade cancer/Gleason score 6 = 10, clinically significant cancer/Gleason score ≥7 = 53), 15 prostatitis, and 26 negative biopsies. Prostate cancer T1, T2, and ADC (mean ± SD, 1660 ± 270 milliseconds, 56 ± 20 milliseconds, 0.70 × 10 ± 0.24 × 10 mm/s) were significantly lower than prostatitis (mean ± SD, 1730 ± 350 milliseconds, 77 ± 36 milliseconds, 1.00 × 10 ± 0.30 × 10 mm/s) and negative biopsies (mean ± SD, 1810 ± 250 milliseconds, 71 ± 37 milliseconds, 1.00 × 10 ± 0.33 × 10 mm/s). For cancer versus prostatitis, ADC was sensitive and T2 specific with comparable area under curve (AUC; (AUCT2 = 0.71, AUCADC = 0.79, difference between AUCs not significant P = 0.37). T1 + ADC (AUCT1 + ADC = 0.83) provided the best separation between cancer and negative biopsies. Low-grade cancer T2 and ADC (mean ± SD, 75 ± 29 milliseconds, 0.96 × 10 ± 0.34 × 10 mm/s) were significantly higher than clinically significant cancers (mean ± SD, 52 ± 16 milliseconds, 0.65 ± 0.18 × 10 mm/s), and T2 + ADC (AUCT2 + ADC = 0.91) provided the best separation.
conclusionsT1 and T2 relaxometry combined with ADC mapping may be useful for quantitative characterization of prostate cancer grades and differentiating cancer from noncancers for PZ lesions seen on T2-weighted images.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.